Resources from the same session
LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study
Presenter: Neeraj Agarwal
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
577O - PRINCE: Interim analysis of the phase Ib study of <sup>177</sup>Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Shahneen Sandhu
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA25 - Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Andrew Armstrong
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA24
Presenter: Cora Sternberg
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Cora Sternberg
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
Invited Discussant 577O
Presenter: Joaquin Mateo
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
Invited Discussant LBA25
Presenter: Stephane Oudard
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Stephane Oudard
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast